The line between educating healthcare professionals and wooing them can still be fuzzy, which is impacting what doctors ...
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...
Attempting to bring new medicines to market is an inherently risky endeavor, with sponsors ultimately failing more than 90% of the time. But rare disease development is even harder; there are fewer ...
Last year, Bristol Myers Squibb put a spotlight on the kind of cash that comes with pharma’s conviction in a new oncology strategy. The drugmaker agreed to pay BioNTech $1.5 billion upfront and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results